Press Releases From 03/26/2012 Until 05/22/2015

Viewing from to Change
 

PennyTrackers.com Profiles the Best Penny Stock Picks: (OTC Pink: AQUI), (OTCQB: REVO), (OTC Pink: SBRH), (OTC Pink: SRGE)

www.pennytrackers.com is issuing a volume alert on the following stocks (OTC Pink: AQUI), (OTCQB: REVO), (OTC Pink: SBRH), (OTC Pink: SRGE) New York, NY 10/05/2012

Fat Burning Furnace Review - Reduce Your Weight and Look Slimmer

People more often search for ways which could be easier as well as effective to help them loose excess weight. You might end up going to a fat burning clinic but still keep carrying those extra fats despite making efforts. The fact that these clinics view fat people as their clients makes them provide limited suggestions which means you would not lose the weight you wanted to. A fat burning furnace can be the option that could really work wonders to help you reduce the extra weight. Now, you might ask ‘’what is fat burning furnace?’’. Well it is an ultimate system through which you can reduce your weight drastically without making much effort.

Skin Inflammation - Pipeline Review, H2 2012 New Report

LogoSkin Inflammation - Pipeline Review, H2 2012, provides an overview of the Skin Inflammation therapeutic pipeline. This report provides information on the therapeutic development for Skin Inflammation, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Skin Inflammation. 'Skin Inflammation - Pipeline Review, H2 2012' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Mycoses - Pipeline Review, H2 2012 New Report

LogoMycoses - Pipeline Review, H2 2012, provides an overview of the Mycoses therapeutic pipeline. This report provides information on the therapeutic development for Mycoses, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Mycoses. 'Mycoses - Pipeline Review, H2 2012' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Bone Metastasis - Pipeline Review, H2 2012 New Report

LogoBone Metastasis - Pipeline Review, H2 2012, provides an overview of the Bone Metastasis therapeutic pipeline. This report provides information on the therapeutic development for Bone Metastasis, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Bone Metastasis. 'Bone Metastasis - Pipeline Review, H2 2012' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Movement Disorders - Pipeline Review, H2 2012 New Report

LogoMovement Disorders - Pipeline Review, H2 2012, provides an overview of the Movement Disorders therapeutic pipeline. This report provides information on the therapeutic development for Movement Disorders, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Movement Disorders. 'Movement Disorders - Pipeline Review, H2 2012' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Metastatic Prostate Cancer - Pipeline Review, H2 2012 New Report

LogoMetastatic Prostate Cancer - Pipeline Review, H2 2012, provides an overview of the Metastatic Prostate Cancer therapeutic pipeline. This report provides information on the therapeutic development for Metastatic Prostate Cancer, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Metastatic Prostate Cancer. 'Metastatic Prostate Cancer - Pipeline Review, H2 2012' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Contraceptives - Pipeline Review, H2 2012 New Report

LogoContraceptives - Pipeline Review, H2 2012, provides an overview of the Contraceptives therapeutic pipeline. This report provides information on the therapeutic development for Contraceptives, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Contraceptives. 'Contraceptives - Pipeline Review, H2 2012' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Astrocytoma - Pipeline Review, H2 2012 New Report

LogoAstrocytoma - Pipeline Review, H2 2012, provides an overview of the Astrocytoma therapeutic pipeline. This report provides information on the therapeutic development for Astrocytoma, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Astrocytoma. 'Astrocytoma - Pipeline Review, H2 2012' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Orthomyxoviridae Infections - Pipeline Review, H2 2012 New Report

LogoOrthomyxoviridae Infections - Pipeline Review, H2 2012, provides an overview of the Orthomyxoviridae Infections therapeutic pipeline. This report provides information on the therapeutic development for Orthomyxoviridae Infections, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Orthomyxoviridae Infections. 'Orthomyxoviridae Infections - Pipeline Review, H2 2012' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Abscess - Pipeline Review, H1 2012 New Report

LogoAbscess - Pipeline Review, H1 2012, provides an overview of the Abscess therapeutic pipeline. This report provides information on the therapeutic development for Abscess, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Abscess. 'Abscess - Pipeline Review, H1 2012' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Adrenoleukodystrophy (Adrenomyeloneuropathy/ Schilder-Addison Complex) - Pipeline Review, H1 2012 New Report

LogoAdrenoleukodystrophy (Adrenomyeloneuropathy/ Schilder-Addison Complex) - Pipeline Review, H1 2012, provides an overview of the Adrenoleukodystrophy (Adrenomyeloneuropathy/ Schilder-Addison Complex) therapeutic pipeline. This report provides information on the therapeutic development for Adrenoleukodystrophy (Adrenomyeloneuropathy/ Schilder-Addison Complex), complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Adrenoleukodystrophy (Adrenomyeloneuropathy/ Schilder-Addison Complex). 'Adrenoleukodystrophy (Adrenomyeloneuropathy/ Schilder-Addison Complex) - Pipeline Review, H1 2012' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Exanthema - Pipeline Review, H1 2012 New Report

LogoExanthema - Pipeline Review, H1 2012, provides an overview of the Exanthema therapeutic pipeline. This report provides information on the therapeutic development for Exanthema, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Exanthema. 'Exanthema - Pipeline Review, H1 2012' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Basal Cell Carcinoma (Basal Cell Epithelioma) - Pipeline Review, H1 2012 New Report

LogoBasal Cell Carcinoma (Basal Cell Epithelioma) - Pipeline Review, H1 2012, provides an overview of the Basal Cell Carcinoma (Basal Cell Epithelioma) therapeutic pipeline. This report provides information on the therapeutic development for Basal Cell Carcinoma (Basal Cell Epithelioma), complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Basal Cell Carcinoma (Basal Cell Epithelioma). 'Basal Cell Carcinoma (Basal Cell Epithelioma) - Pipeline Review, H1 2012' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Alpha-Mannosidosis - Pipeline Review, H1 2012 New Report

LogoAlpha-Mannosidosis - Pipeline Review, H1 2012, provides an overview of the Alpha-Mannosidosis therapeutic pipeline. This report provides information on the therapeutic development for Alpha-Mannosidosis, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Alpha-Mannosidosis. 'Alpha-Mannosidosis - Pipeline Review, H1 2012' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Brain Cancer - Pipeline Review, H2 2012 New Report

LogoBrain Cancer - Pipeline Review, H2 2012, provides an overview of the Brain Cancer therapeutic pipeline. This report provides information on the therapeutic development for Brain Cancer, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Brain Cancer. 'Brain Cancer - Pipeline Review, H2 2012' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Bacterial Conjunctivitis - Pipeline Review, H1 2012 New Report

LogoBacterial Conjunctivitis - Pipeline Review, H1 2012, provides an overview of the Bacterial Conjunctivitis therapeutic pipeline. This report provides information on the therapeutic development for Bacterial Conjunctivitis, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Bacterial Conjunctivitis. 'Bacterial Conjunctivitis - Pipeline Review, H1 2012' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Alpha- Antitrypsin Deficiency - Pipeline Review, H1 2012 New Report

LogoAlpha- Antitrypsin Deficiency - Pipeline Review, H1 2012, provides an overview of the Alpha- Antitrypsin Deficiency therapeutic pipeline. This report provides information on the therapeutic development for Alpha- Antitrypsin Deficiency, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Alpha- Antitrypsin Deficiency. 'Alpha- Antitrypsin Deficiency - Pipeline Review, H1 2012' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Fungal Infections - Pipeline Review, H2 2012 New Report

LogoFungal Infections - Pipeline Review, H2 2012, provides an overview of the Fungal Infections therapeutic pipeline. This report provides information on the therapeutic development for Fungal Infections, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Fungal Infections. 'Fungal Infections - Pipeline Review, H2 2012' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Brain Metastasis - Pipeline Review, H2 2012 New Report

LogoBrain Metastasis - Pipeline Review, H2 2012, provides an overview of the Brain Metastasis therapeutic pipeline. This report provides information on the therapeutic development for Brain Metastasis, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Brain Metastasis. 'Brain Metastasis - Pipeline Review, H2 2012' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Leukocyte Disorders (White Blood Cell Disorders) - Pipeline Review, H2 2012 New Report

LogoLeukocyte Disorders (White Blood Cell Disorders) - Pipeline Review, H2 2012, provides an overview of the Leukocyte Disorders (White Blood Cell Disorders) therapeutic pipeline. This report provides information on the therapeutic development for Leukocyte Disorders (White Blood Cell Disorders), complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Leukocyte Disorders (White Blood Cell Disorders). 'Leukocyte Disorders (White Blood Cell Disorders) - Pipeline Review, H2 2012' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Ependymoma - Pipeline Review, H1 2012 New Report

LogoEpendymoma - Pipeline Review, H1 2012, provides an overview of the Ependymoma therapeutic pipeline. This report provides information on the therapeutic development for Ependymoma, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Ependymoma. 'Ependymoma - Pipeline Review, H1 2012' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Islet Cell Carcinoma (Insulinoma) - Pipeline Review, H1 2012 New Report

LogoIslet Cell Carcinoma (Insulinoma) - Pipeline Review, H1 2012, provides an overview of the Islet Cell Carcinoma (Insulinoma) therapeutic pipeline. This report provides information on the therapeutic development for Islet Cell Carcinoma (Insulinoma), complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Islet Cell Carcinoma (Insulinoma). 'Islet Cell Carcinoma (Insulinoma) - Pipeline Review, H1 2012' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Typhoid Fever - Pipeline Review, H1 2012 New Report

LogoTyphoid Fever - Pipeline Review, H1 2012, provides an overview of the Typhoid Fever therapeutic pipeline. This report provides information on the therapeutic development for Typhoid Fever, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Typhoid Fever. 'Typhoid Fever - Pipeline Review, H1 2012' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Muscle Spasm - Pipeline Review, H1 2012 New Report

LogoMuscle Spasm - Pipeline Review, H1 2012, provides an overview of the Muscle Spasm therapeutic pipeline. This report provides information on the therapeutic development for Muscle Spasm, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Muscle Spasm. 'Muscle Spasm - Pipeline Review, H1 2012' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.